Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.

Szczegóły
Abstrakt

Tytuł:: Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.
Autorzy:: Gaspar EB; Animal Health Department, Embrapa Southern Region Animal Husbandry, Bagé, Brazil.
Prudencio CR; Department of Immunology, Adolfo Lutz Institute, São Paulo, Brazil.
De Gaspari E; Department of Immunology, Adolfo Lutz Institute, São Paulo, Brazil.
Źródło:: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Sep 02; Vol. 17 (9), pp. 2965-2968. Date of Electronic Publication: 2021 May 05.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
MeSH Terms:: COVID-19*
Meningococcal Vaccines*
Vaccines*
Bacterial Outer Membrane Proteins ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
References:: PLoS One. 2018 Jan 26;13(1):e0191286. (PMID: 29373591)
Int J Surg. 2020 Jun;78:185-193. (PMID: 32305533)
Clin Diagn Lab Immunol. 1998 Sep;5(5):732-6. (PMID: 9729544)
J Med Virol. 2021 May;93(5):3092-3104. (PMID: 33565617)
Lancet. 1991 Nov 2;338(8775):1093-6. (PMID: 1682541)
Vaccine. 2011 Sep 16;29(40):7100-6. (PMID: 21803101)
Clin Vaccine Immunol. 2009 Feb;16(2):156-62. (PMID: 19109451)
Pharmacol Res. 2020 Jun;156:104791. (PMID: 32302707)
Cytokine. 2021 Jan;137:155323. (PMID: 33045526)
Pathog Dis. 2020 Jul 1;78(5):. (PMID: 32639524)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Front Oncol. 2017 Nov 07;7:253. (PMID: 29164053)
Vaccine. 2006 Jan 12;24(2):206-14. (PMID: 16115701)
Nat Commun. 2020 Jun 10;11(1):2920. (PMID: 32523109)
Drugs. 2014 Jan;74(1):15-30. (PMID: 24338083)
Vaccines (Basel). 2020 Sep 17;8(3):. (PMID: 32957610)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
NIPH Ann. 1991 Dec;14(2):195-207; discussion 208-10. (PMID: 1812432)
Vaccine. 2011 Oct 26;29(46):8293-301. (PMID: 21893142)
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. (PMID: 32747721)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
Hum Vaccin. 2008 Jan-Feb;4(1):67-73. (PMID: 17881890)
Nat Immunol. 2017 May 18;18(6):612-621. (PMID: 28518156)
EBioMedicine. 2021 Jan;63:103197. (PMID: 33422991)
Trends Immunol. 2020 Dec;41(12):1100-1115. (PMID: 33132005)
Lancet. 2021 Feb 20;397(10275):671-681. (PMID: 33545094)
NPJ Vaccines. 2019 Jul 8;4:24. (PMID: 31312527)
Natl Sci Rev. 2020 Jun;7(6):1003-1011. (PMID: 34676126)
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104. (PMID: 20133740)
Nat Microbiol. 2020 Apr;5(4):562-569. (PMID: 32094589)
Int J Mol Sci. 2020 Jun 21;21(12):. (PMID: 32575921)
Vaccine. 2021 Mar 5;39(10):1473-1475. (PMID: 33581919)
Immunobiology. 2018 Dec;223(12):750-760. (PMID: 30055864)
Front Immunol. 2020 Sep 17;11:570018. (PMID: 33042151)
J Med Virol. 2020 Jun;92(6):548-551. (PMID: 32096567)
Vaccine. 2017 Sep 25;35(40):5373-5380. (PMID: 28866291)
Semin Immunol. 2020 Aug;50:101433. (PMID: 33309166)
J Immunol. 2013 Apr 15;190(8):4092-102. (PMID: 23514742)
Mol Ther. 2017 Apr 5;25(4):989-1002. (PMID: 28215994)
Contributed Indexing:: Keywords: Neisseria meningitidis; OMV; SARS-Cov-2; immune response
Substance Nomenclature:: 0 (Bacterial Outer Membrane Proteins)
0 (COVID-19 Vaccines)
0 (Meningococcal Vaccines)
0 (Spike Glycoprotein, Coronavirus)
0 (Vaccines)
0 (spike protein, SARS-CoV-2)
Entry Date(s):: Date Created: 20210505 Date Completed: 20210823 Latest Revision: 20240403
Update Code:: 20240403
PubMed Central ID:: PMC8108191
DOI:: 10.1080/21645515.2021.1920272
PMID:: 33950776
: Czasopismo naukowe

Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV.

Informacja